Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection

This study has been terminated.
Aventis Pharmaceuticals
Information provided by:
French National Agency for Research on AIDS and Viral Hepatitis Identifier:
First received: September 12, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted